Oncolys Biopharma Inc represents values of innovation, dedication, and integrity. With a strong corporate philosophy focused on transforming patients' lives through biopharmaceutical advancements, Oncolys Biopharma strives to develop cutting-edge therapies for various medical conditions. The company's commitment to research and development is guided by a vision of improving global health and serving unmet medical needs. Oncolys Biopharma emphasizes collaboration, employing the expertise of talented scientists, clinicians, and industry professionals to drive progress in the field of biotechnology. Through their relentless pursuit of breakthrough treatments, Oncolys Biopharma aims to make a significant impact on patients' lives worldwide.

Oncolys Biopharma Inc is primarily present in Japan and the United States.

Oncolys Biopharma Inc has achieved several significant milestones. One notable milestone is the successful completion of Phase 1 clinical trials for their lead drug candidate. In addition, the company has secured various strategic partnerships and collaborations with renowned institutions and pharmaceutical companies. Oncolys Biopharma Inc's continuous dedication to research and development has resulted in the development of innovative therapies and breakthrough technologies. Moreover, the company's commitment to patient care and safety has led to the acquisition of regulatory approvals for their drug candidates. These achievements underscore Oncolys Biopharma Inc's position as a leader in the biopharmaceutical industry.

Oncolys Biopharma Inc is a leading biopharmaceutical company specializing in the development of innovative therapies for the treatment of cancer. Established in [year], the company has a rich history in the field of oncology and has made significant contributions towards improving patient outcomes. Oncolys Biopharma Inc focuses on the research, development, and commercialization of novel immunotherapies and targeted therapies. With a dedicated team of experienced scientists and researchers, the company strives to advance the understanding of cancer biology and develop innovative treatments tailored to specific types of cancer. Driven by a commitment to improving the lives of patients, Oncolys Biopharma Inc has established strategic collaborations with global partners to accelerate the development of its pipeline. Through its cutting-edge technologies and ongoing clinical trials, the company aims to revolutionize cancer treatment and bring hope to patients worldwide.

The main competitors of Oncolys Biopharma Inc in the market include companies like XYZ Pharmaceuticals, ABC Therapeutics, and PQR Biotech. These companies also specialize in the development and commercialization of innovative biopharmaceutical products. While Oncolys Biopharma Inc focuses on pioneering novel cancer treatments, its competitors strive to create breakthrough therapies in the field of oncology. As Oncolys Biopharma Inc continues to make advancements in cancer research, it faces competition from these prominent players in the biopharmaceutical industry, who are all working towards improving patient outcomes and addressing unmet medical needs.

Oncolys Biopharma Inc is primarily active in the pharmaceutical industry.

The business model of Oncolys Biopharma Inc revolves around developing innovative solutions for the treatment of cancer. They primarily focus on the research and development of oncolytic virus therapies to target and destroy cancer cells. By utilizing their expertise in biotechnology, Oncolys Biopharma aims to provide effective and safe treatment options to improve the lives of cancer patients. With a strong dedication to advancing oncology treatments, the company strives to make significant contributions in the field of cancer therapeutics. Through their strategic collaborations and clinical trials, Oncolys Biopharma is committed to bringing novel therapies to market and addressing the unmet medical needs of cancer patients.

Коефициентът на цена спрямо печалбата (КЦП) на Oncolys Biopharma е -20,12.

Коефициентът на цена към оборот (KUV) на Oncolys Biopharma е 10,41.

AlleAktien качественият резултат за Oncolys Biopharma е 5/10.

очаквана Oncolys Biopharma оборотът е 1,01 млрд. JPY.

очаквана Oncolys Biopharma печалба е -522,80 млн. JPY.

Oncolys Biopharma Inc is a biotechnology company focused on researching and developing therapies for cancer. The company is based in Japan and has a branch in the USA.

Oncolys Biopharma разпределя дивидента от 0 JPY на плащания годишно.

Дивидентата за Oncolys Biopharma в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Oncolys Biopharma е JP3202170001.

WKN на Oncolys Biopharma е A1W94N.

Тикерът на Oncolys Biopharma е 4588.T.

През последните 12 месеца Oncolys Biopharma изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Oncolys Biopharma да изплати дивиденда в размер на 0 JPY.

Дивидентната доходност на Oncolys Biopharma в момента е .

Oncolys Biopharma изплаща дивидент на тримесечие. Той се разпределя в месеците .

Oncolys Biopharma платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 JPY. Това съответства на дивидентна доходност от 0 %.

Oncolys Biopharma се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Oncolys Biopharma на 10.09.2024 г. в размер на 0 JPY, трябваше да притежавате акцията в портфейла си преди Ex-деня на 10.09.2024 г..

Последното дивидентно плащане беше извършено на 10.09.2024 г..

През година 2023 Oncolys Biopharma изплати 0 JPY под формата на дивиденти.

Дивидентите от Oncolys Biopharma се изплащат в JPY.